Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.

Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ.

Int J Gynecol Cancer. 2016 May;26(4):763-9. doi: 10.1097/IGC.0000000000000654. Review.

PMID:
26905326
2.

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.

Papa A, Caruso D, Strudel M, Tomao S, Tomao F.

J Transl Med. 2016 Sep 15;14:267. doi: 10.1186/s12967-016-1027-1. Review.

3.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
4.

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.

Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.

Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367. Review.

5.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
6.

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, Pérez JM.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):39-53. Review.

PMID:
18221025
7.

Poly(ADP-ribose) polymerase activity and inhibition in cancer.

Dulaney C, Marcrom S, Stanley J, Yang ES.

Semin Cell Dev Biol. 2017 Mar;63:144-153. doi: 10.1016/j.semcdb.2017.01.007. Epub 2017 Jan 10. Review.

PMID:
28087320
8.

Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.

Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.

Biochem Pharmacol. 2016 May 1;107:29-40. doi: 10.1016/j.bcp.2016.02.015. Epub 2016 Feb 24.

PMID:
26920250
9.

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.

Vormoor B, Curtin NJ.

Curr Opin Oncol. 2014 Jul;26(4):428-33. doi: 10.1097/CCO.0000000000000091. Review.

10.

Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.

McCann KE.

Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428. Review.

PMID:
29251678
11.

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Review.

PMID:
20645701
12.

New PARP targets for cancer therapy.

Vyas S, Chang P.

Nat Rev Cancer. 2014 Jul;14(7):502-9. doi: 10.1038/nrc3748. Epub 2014 Jun 5. Review.

13.

Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.

He JX, Yang CH, Miao ZH.

Acta Pharmacol Sin. 2010 Sep;31(9):1172-80. doi: 10.1038/aps.2010.103. Epub 2010 Aug 2. Review.

14.

Inhibitory PARP w terapii raka jajnika.

Kruczała MA, Grela-Wojewoda A, Cedrych I.

Ginekol Pol. 2016;87(2):131-4. doi: 10.17772/gp/59268. Review. English, Polish.

15.

DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.

Rabenau K, Hofstatter E.

Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29. Review.

PMID:
27368114
16.

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.

Parkes EE, Kennedy RD.

Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Review.

17.

The current status of PARP inhibitors in ovarian cancer.

McLachlan J, George A, Banerjee S.

Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Review.

PMID:
27716873
18.

Targeted therapy for brain tumours: role of PARP inhibitors.

Leonetti C, Biroccio A, Graziani G, Tentori L.

Curr Cancer Drug Targets. 2012 Mar;12(3):218-36. Review.

PMID:
22268386
19.

Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?

Hottiger MO.

Expert Opin Ther Targets. 2015;19(9):1149-52. doi: 10.1517/14728222.2015.1073262. Epub 2015 Jul 27.

PMID:
26212149
20.

Supplemental Content

Support Center